Figure 3.

Tv1 significantly reduces tumor growth in in vivo tumor allograft mouse model. (a) Tumor volumes over a period of 18-day treatment showing significant reduction in tumor sizes in the first phase of treatment (1–8 day) in high (Hd-0.8 mg/kg body weight) and low (Ld-0.08 mg/Kg body weight) dose treated group and a highly significant increase in the tumor volumes in no treatment groups. * p < 0.01 compared with day 1, # p < 0.01 when compared with no treatment group at respective time. (b) In the comparison of no treatment and Tv1 high dose treated tumor volumes throughout the treatment period, Tv1 treated mice had a significantly smaller tumor volume. Shown is the comparison of tumor volume of just one tumor from the no treatment group with the tumor volume of the high dose treated group. ** p < 0.001 compared with no treatment group. Values are presented as mean ± standard error. Results are presented as mean ± Standard deviation. Analysis of variance (ANOVA) was used for statistical comparison between control and various treated groups.